STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter.STAT+ subscribers can sign up here to get it delivered to their inbox.…
A drug for a rare disease is evaluated in a small clinical trial.
The treatment is modestly effective with manageable side effects.
STAT+: Commure terminates payments under its customer referral programs tied to AI products
Commure, a $7 billion health software company that sells artificial intelligence tools to medical clinics, has terminated a program through which it was paying parties for referrals to new customers, according to company emails obtained by STAT.…
The emails, sent by Commure’s chief legal officer, Dan Brian, inform m…
Opinion: MAHA and insurance companies both want to treat human bodies like cars
After doing three loops around the parking lot, you finally see a free spot.You step on the gas to claim it, but an SUV cuts in front of you and steals the space.…
You stomp on the brakes, jerking to a halt.
You might forgive the other driver, but your Toyota remembers.
How will legal challenges fare against CMS rule on gender-affirming care?
The Trump administration’s campaign to eradicate transgender health care for young people has run into a series of legal roadblocks: Judges have ruled against Justice Department subpoenas, a declaration from the health secretary, and parts of the president’s executive order halting all federal support for this care.…
But a new rule finalized this week by the Centers for Medicare and Med…
The agency announced Tuesday it was barring the use of federal Medicai…
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
The Food and Drug Administration on Thursday approved an oral treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of medicine for the blood cancer and the first drug cleared by U.…
regulators using a more sensitive measure of remission.
The Bristol drug, iberdomide, will be sold under the brand name Zenbex…
STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more
And so, another working week will soon come to a close.Not a moment too soon, yes?This is, you may recall, our treasured signal to daydream about weekend plans.…
Our agenda is still taking shape, but we plan on promenading with the …
We also hope to have time for our weekly listening party, where the ro…
Today, we’re looking at a new multiple myeloma approval for Bristol Myers Squibb, PBMs embracing TrumpRx price comparisons, and Novartis winning a key U.…
patent fight over Entresto.
My son built a structurally sound bridge yesterday out of latticed twi…
Luigi Mangione pleads guilty to federal stalking charges in the killing of UnitedHealthcare CEO
NEW YORK — Luigi Mangione pleaded guilty on Friday to federal stalking charges in the killing of UnitedHealthcare CEO Brian Thompson, admitting matter-of-factly that he trailed the executive to an investor conference in 2024 and gunned him down on a New York City street.…
Mangione, 28, said he even used a ruse to glean information about the …